A practical reference on anti-doping category: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
== Clinical significance == Progression of epithelial cancer often relies on deep and regional lymph node invasion. The lamina propria, being one of the barriers to the submucosa, is an area where epithelial cancer invasion is of significance since lymphatic invasion is an independent predictor of lymph node metastasis, especially in gastric cancer. As soon as the tumors breach the basement membrane and reach the lamina propria, they are exposed to lymphatics which may increase the rate of metastasis and cancer progression. Deeper invasion into the submucosa will increase the exposure to lymphatics. Long-standing inflammation is a risk factor for the development of cancer. The lamina propria macrophages when under much stress release pro-inflammatory signals that may lead to increased probability of developing cancer. An example of this is the overactivation of the IL-6/STAT3 pathway, which has been linked to colitis-associated cancer.
== Pathophysiology == The main etiologic factor of ACC is unknown, although families with Li–Fraumeni syndrome, caused by an inherited inactivation mutation in TP53, have increased risk. Several genes have been shown to be recurrently mutated, including TP53, CTNNB1, MEN1, PRKAR1A, RPL22, and DAXX. The telomerase gene TERT is often amplified while ZNRF3 and CDKN2A are often homozygously deleted. The genes h19, insulin-like growth factor II (IGF-II), and p57kip2 are important for fetal growth and development. They are located on chromosome 11p. Expression of the h19 gene is markedly reduced in both nonfunctioning and functioning adrenal cortical carcinomas, especially in tumors producing cortisol and aldosterone. Also, a loss occurs of activity of the p57kip2 gene product in virilizing adenomas and adrenal cortical carcinomas. In contrast, IGF-II gene expression has been shown to be high in adrenal cortical carcinomas. Finally, c-myc gene expression is relatively high in neoplasms, and it is often linked to poor prognosis. Bilateral adrenocortical tumors are less common than unilateral. The majority of bilateral tumours can be distinguished according to size and aspect of the nodules: primary pigmented nodular adrenocortical disease, which can be sporadic or part of Carney complex, and primary bilateral macro nodular adrenal hyperplasia.Metastasis is most commonly to the liver and lung.
== Background == High performance liquid chromatography (HPLC) and electron ionization mass spectrometry (EIMS) are two analytical techniques that, in principle, seem to be incompatible. However, because these two approaches share a great deal of applications in the analysis of suitable molecules, typically less than 1000 u, a large effort has been devoted by the scientific community to develop a reliable, easy-to-use, and flawless interface. The first successful and commercially available device to combine EI and HPLC was designed by Willoughby and Browner in 1984. It was based on the conversion of the solute into a beam of particles, after the formation of spray droplets and the elimination of the solvent vapors through a multi-stage momentum separator. Although its efficient interfacing mechanism and a unique trait, particle beam performance was sometimes inadequate to an increasing number of new, demanding applications and was quickly replaced by a family of atmospheric pressure ionization-based interfaces (API) when they became commercially available. However, the possibility to record an EI spectrum from an HPLC application remained a challenge for a long time. The first Direct-EI prototype was first presented in 2002 and proposed an innovative approach that improved interfacing performance compared to that of particle beam and opened new opportunities for LC-MS applications.
== Treatment == Disease progression may be slowed with immunosuppressives and other medications, and esophageal reflux, pulmonary hypertension and Raynaud phenomenon may benefit from symptomatic treatment. However, there is no cure for this disease as there is no cure for scleroderma in general.
=== Detection in body fluids === Stanozolol is subject to extensive hepatic biotransformation by a variety of enzymatic pathways. The primary metabolites are unique to stanozolol and are detectable in the urine for up to 10 days after a single 5–10 mg oral dose. Methods for detection in urine specimens usually involve gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry.
Sources: en.wikipedia.org
In an 18-month double-blind, placebo controlled study, the effects of Preotact on the fracture incidence in 2532 women with postmenopausal osteoporosis was studied. Approximately 19% of patients had a prevalent vertebral fracture at baseline and the mean lumbar T-score of -3.0 in both active and placebo arm. Compared to the placebo group, there was a 61% relative risk reduction of a new vertebral fracture at month 18 for the women in the Preotact group. To prevent one or more new vertebral fractures, 48 women had to be treated for a median of 18 months for the total population. For patients who were already fractured, the number needed to treat was 21.
Charge concentration in the droplets during evaporation. Electrochemical processes stemming from the electrostatic potential of the capillary. Unlike in TSI, the analyte ions produced by ESI may carry a different amount of charge than the same analyte would carry in the solution. That is, an analyte that is naturally occurring as M+ in the solution may end up becoming a stream of ions containing a mixture of M+, M2+, M3+, etc. A large molecule can carry much charge. Typical proteins can carry many protons due to the presence of basic amino acid side chains, resulting in peaks at m/z = 600–2000 for proteins with a molecular weight ~200,000 Da. This is convenient, since it means the ion would not exceed the m/z limits on typical mass analyzers.
White tried to use taking more pictures as an excuse to stay out longer, and McDivitt had to coax him in. He finally came back in after a total of approximately 23 minutes, almost 10 minutes later than was planned. He said: "It's the saddest moment of my life." By the time he got in, the spacecraft had entered darkness. The hatch proved to be as stubborn to relatch as it was to open. This would have been disastrous, resulting in both men's deaths on reentry. McDivitt was able to fix the mechanism once again, so White could close it, about 20 minutes after he got in. The mission plan called for opening the hatch again to throw out White's now-unnecessary EVA equipment, but McDivitt elected not to do this, instead keeping the unnecessary equipment on board for the rest of the flight. They powered down the spacecraft's maneuvering system, intending to drift for the next two-and-a-half days to conserve the remaining fuel. They also intended to sleep alternate four-hour periods, but this turned out to be extremely difficult with the constant radio communications and the small cabin, about the size of the front seats of a compact car. White's 20-minute space walk was the mission's highlight, with McDivitt's photographs being published worldwide. These also showed White wearing an Omega Speedmaster chronograph watch on his spacesuit sleeve, one of two makes which had been approved by NASA for space use following extensive tests. Omega were unaware of these tests or the fact that its product was going to be used in space, until the photos.
Newsom has also been condemned and criticized by humanitarian and queer rights organizations such as the Human Rights Campaign, National Center for LGBTQ Rights, and the Los Angeles LGBT Center. The American Civil Liberties Union issued a statement saying it was "saddened and angered" by Newsom's conduct, calling on him to "lean into his role as a leader on LGBTQ+ issues and reject the hateful, extremist rhetoric". In 2026, Newsom vetoed a bill that would have protected transgender healthcare and abortion providers from being extradited to other states. In his veto message, he said he supported protecting these services and their providers but expressed concern about the executive function of extradition.
== Further reading == Chiang YS, Gelfand TI, Kister AE, Gelfand IM (2007). "New classification of supersecondary structures of sandwich-like proteins uncovers strict patterns of strand assemblage". Proteins. 68 (4): 915–921. doi:10.1002/prot.21473. PMID 17557333. S2CID 29904865.
Sources: en.wikipedia.org
=== Side effects === Xylazine overdose is often fatal in humans. Because it is used as a drug adulterant, the symptoms caused by the drugs accompanying xylazine administration vary between individuals. The most common side-effects in humans associated with xylazine administration include bradycardia, respiratory depression, hypotension, transient hypertension secondary to α1-adrenergic receptor stimulation, and other central and hemodynamic changes. Xylazine significantly decreases heart rate in animals that are not pre-medicated with medications that have anticholinergic effects. Symptoms that can occur following overdose are areflexia, asthenia, ataxia, blurred vision, disorientation, dizziness, dysarthria, dysmetria, fainting, hyporeflexia, somnolence, coma, apnea, premature ventricular contraction, tachycardia, miosis, and hyperglycaemia. Rarely, hypotonia, urinary incontinence, and nonspecific electrocardiographic ST segment changes occur. Following a human overdose, symptoms can last for 8–72 hours, varying based on xylazine's combined usage with other drugs.
== Cancer == Recently, SCF complexes have become an attractive anti-cancer target because of their upregulation in some human cancers and their biochemically distinct active sites. Though many of the aforementioned FBPs have been implicated in cancer, cytotoxicity has been a limiting factor of drug development. Skp2-targeting anti-sense oligonucleotides and siRNAs are in the drug development pipeline. Preliminary studies have shown that Skp2 downregulation can inhibit the growth of melanomas, lung cancer cells, oral cancer cells, and glioblastoma cells. βTRCP-targeting siRNAs have been shown to sensitize breast cancer cells and cervical cancer cells to existing chemotherapies.
The experiences reported by women living with HIV suggest that stigma and discrimination within healthcare settings plays a large role in coercive and forced sterilization. These women are particularly vulnerable when accessing maternal health services.
Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive disorder. It is taken orally. Side effects of gepirone include dizziness, nausea, insomnia, abdominal pain, and dyspepsia (indigestion). Gepirone acts as a partial agonist of the serotonin 5-HT1A receptor. An active metabolite of gepirone, 1-(2-pyrimidinyl)piperazine, is an α2-adrenergic receptor antagonist. Gepirone is a member of the azapirone group of compounds. Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. It was approved for the treatment of major depressive disorder in the United States in September 2023. This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.